Protective effect of nifedipine against carrageenan-induced inflammation.
Administration of carrageenan (CA; 0.5 mg) to the plantar tissue of rats resulted in reversible inflammatory injury. The edema was monitored by changes in paw volume using a plethysmometer. Simultaneous administration of CA and nifedipine, intraperitoneally, at different doses (10, 20 and 50 mg/kg) prevented the inflammatory action, and the effect was dose- and time-dependent. In order to improve the nifedipine effects, we prepared liposomed nifedipine which, administered intraperitoneally, showed a greater anti-inflammatory action. In the presence of the L-type channel agonist Bay K 8644, the inflammation produced by CA increased and it was counteracted by free or liposomed nifedipine. The significance of these findings with respect to the mechanism of the anti-inflammatory action of nifedipine is discussed.
Sánchez
S
S
Unitat de Farmacologia, Facultat Odontologia, Universitat de Barcelona, España.
Bartrons
R
R
Rodríguez
L
L
González
P
P
Planas
M E
ME
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D002351:Carrageenan; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D005260:Female; D006614:Hindlimb; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D008081:Liposomes; D009543:Nifedipine / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000893:Anti-Inflammatory Agents; D002121:Calcium Channel Blockers; D004337:Drug Carriers; D008081:Liposomes; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D002351:Carrageenan; D009543:Nifedipine